Cipla launches Yurpeak® (tirzepatide) for the treatment of Obesity and Type 2 Diabetes

Cipla Limited today announced the launch of Yurpeak (tirzepatide), a oneweekly injectable therapy for managing obesity and type 2 diabetes mellitus (T2DM) - two of the country's most pressing health challenges.

- Media News

Cipla has the rights to distribute and promote Yurpeak® - the second brand of Lilly's tirzepatide in India, after Lilly received DCGI approval. Commenting on the launch, Achin Gupta, Global Chief Operating Officer, Cipla Limited, said: "The launch of Yurpeak® marks a transformative moment in the fight against obesity and type 2 diabetes mellitus, two of India's chronic conditions with a heavy burden. Cipla is entering this space with the same depth of expertise and scientific commitment that define our leadership in chronic diseases and in respiratory care. Our focus remains on accelerating access t